Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON
Muh Geot Wong, Vlado Perkovic, John Chalmers, Mark Woodward, Qiang Li, Mark E Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, David Matthews, Bruce Neal, Neil Poulter, Anthony Rodgers, Bryan Williams, Sophia Zoungas
Diabetes Care | AMER DIABETES ASSOC | Published : 2016
Awarded by Medical Research Council
Awarded by National Institute for Health Research
The ADVANCE trial and ADVANCE-ON follow-up study were funded by unrestricted grants from Servier and the Australia National Health and Medical Research Council. M.G.W. reports fees for scientific lectures from AstraZeneca. V.P. reports honoraria for scientific lectures from Boehringer Ingelheim, Merck, AbbVie, Roche, AstraZeneca, and Servier and serves on steering committees and/or advisory boards supported by AbbVie, Astellas, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, and Pfizer. J.C. reports research grants administered through the University of Sydney for the ADVANCE trial and the ADVANCE-ON post-trial study and honoraria from Servier for speaking about these studies at scientific meetings. P.H. is a member of College International de Recherche Servier. B.W. has received honoraria from Servier for lectures at scientific meetings. S.Z. reports past participation in advisory boards and/or receiving honoraria from Amgen Australia, AstraZeneca/Bristol-Myers Squibb Australia, Janssen-Cilag, Merck Sharp & Dohme (Australia), Novartis Australia, Sanofi, Servier Laboratories, and Takeda Australia as well as Monash University undertaking contract work for AstraZeneca Pty Ltd./Bristol-Myers Squibb Australia Pty Ltd. No other potential conflicts of interest relevant to this article were reported.